|
|
News Breaks | | | | January 10, 2013 | | 08:17 EDT |  | OCLS | Oculus spins off Biotechnology business
Oculus Innovative Sciences announced that its board of directors has unanimously approved a spin-off of its novel biotechnology business, Ruthigen. Oculus management is currently working with securities counsel and bankers on a plan to provide equity in Ruthigen to Oculus shareholders. Oculus expects the spinoff to be a tax-free stock distribution and ultimately anticipates Ruthigen to become an independent NASDAQ-traded company. Oculus has retained bankers and financial advisors for the spinoff, and expects the spinoff to be completed in 2013. Execution of the transaction requires further work relative to structure, governance and other significant matters and risks. Upon completion of the spinoff, Hoji Alimi, founder and current CEO of Oculus, will remain on the board at Oculus and serve as chairman and CEO of Ruthigen. Jim Schutz, the current COO and director of Oculus, will assume the role of CEO of Oculus, with a new board chair to be elected shortly. Each company will operate with independent management teams and boards to establish separate governance and financials as required by accounting rules. Additional details regarding structure will be determined and disclosed at a later time. Oculus will retain all Microcyn drug and device indications while Ruthigen will focus on RUT58-60, a drug candidate intended for the prevention of infection in trauma and surgical procedures. | |
|
News For OCLS From The Last 14 Days Check below for free stories on OCLS the last two weeks. |
|
|
| There are no results for OCLS |
|
|
|
|
|
|
